Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Study of AMG 145 in Homozygous Familial Hypercholesterolemia
2011-005399-40Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of evolocumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Amgen. Primary endpoint: Percent change in LDL-C from baseline to week 12 (Part A). Started Feb 2012; status: completed.
02
Drugs
evolocumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2011-005399-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005399-40.